TABLE 6.
Anti-OMV IgG GMTs at baseline and after each dose of MenBvac
| Target strain | IgG GMT (95% CI)a
|
||||
|---|---|---|---|---|---|
| Baseline | 6 wk after dose 1 | 6 wk after dose 2 | 6 wk after dose 3 | 1 yr after dose 3 | |
| 44/76-SL | 77.9 (52.3-116.0) | 231.1** (152.2-351.0) | 431.2** (321.8-577.6) | 782.9** (557.8-1098.8) | 214.5**## (141.9-324.4) |
| NZ 98/254 | 56.0 (34.0-92.3) | 130.1** (83.5-202.7) | 164.5 (99.5-272.2) | 302.2** (201.2-453.9) | 144.3**## (94.4-220.8) |
| M01 240013 | 31.5 (21.0-47.3) | 61.8** (41.1-93.0) | 70.5 (47.2-105.4) | 143.3** (95.9-214.2) | 52.9**## (34.8-80.5) |
| M01 240101 | 38.5 (26.9-55.2) | 66.8** (45.7-97.8) | 75.3 (50.6-112.0) | 112.7* (76.5-166.1) | 60.0**# (38.8-92.9) |
| M01 240149 | 47.7 (34.3-66.4) | 87.6** (62.4-123.1) | 100.7 (65.8-154.1) | 182.9** (122.4-273.3) | 91.6**## (64.4-130.1) |
| M01 240185 | 52.5 (33.9-81.2) | 112.5** (70.7-179.0) | 118.4 (73.1-191.9) | 223.2** (142.5-349.6) | 98.8**## (62.2-156.9) |
| M01 240355 | 38.4 (25.3-58.1) | 61.6* (40.6-93.2) | 76.8 (48.0-122.8) | 131.6* (83.2-196.2) | 65.7**# (42.6-101.5) |
a
*, P < 0.05 for change from previous bleed; **, P < 0.001 for change from previous bleed; #, P < 0.05 for change from baseline; ##, P < 0.001 from baseline.